RxDoctor Payments Data

Julie Callanan

Psychiatry · Hyannis, MANPI 1992730089

Payments from drug & device makers

$8,436in general payments, 2019–2025

Across 364 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$1K
  • Otsuka America Pharmaceutical, Inc.$966
  • Alkermes, Inc.$934
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$886
  • Johnson & Johnson$836
  • AbbVie$798
  • plus $3K from 12 others

What the payments were for

  • Food & beverage$8,17497%
  • Education$2623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,436 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Most prescribed under Part D

DrugClaimsCost to plans & patients
Wellbutrin XlBupropion Hcl12$70,745
RexultiBrexpiprazole35$61,986
CaplytaLumateperone Tosylate26$55,851
Invega SustennaPaliperidone Palmitate14$37,033
AuvelityDextromethorphan Hbr/Bupropion18$21,208
VraylarCariprazine Hcl12$16,418
BelsomraSuvorexant18$10,593
Lurasidone Hcl24$9,635
VyvanseLisdexamfetamine Dimesylate18$7,777
TrintellixVortioxetine Hydrobromide12$6,550
Methylphenidate ErMethylphenidate Hcl22$4,496
Desvenlafaxine Succinate ErDesvenlafaxine Succinate28$3,778
Chlorpromazine Hcl13$2,154
Trazodone Hcl97$2,048
Venlafaxine Hcl ErVenlafaxine Hcl41$1,781

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$966$61,98635 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$886$55,85126 claims
Johnson & JohnsonInvega Sustenna$836$37,03314 claims
AbbVieVraylar$798$16,41812 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$546$14,32730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →